Phase 2 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose overall health and ability to carry out daily activities meets a certain minimum level (measured using a standard scale called the ECOG scale, with a score of 0, 1, or 2)
- People who have been confirmed through laboratory testing to have a specific type of ovarian cancer that starts in the lining of the ovary, the peritoneum (the tissue lining the abdomen), or the fallopian tubes
- People whose cancer has been classified as an advanced stage (Stage III or IV)
- People whose cancer cells test positive for a specific protein called claudin 6 (CLDN6)
- People whose heart, liver, kidneys, and other organs are functioning at an adequate level
Who may not be able to join:
- People whose ovarian cancer is of a specific subtype, including clear cell, mucinous, sarcomatous, mixed, low-grade/borderline, or non-epithelial types
- People who have previously received any systemic (whole-body) treatment for this cancer
- People who have previously had surgery related to this cancer
- People who have previously received radiation therapy to the abdomen or pelvis
- People who have recently received chemotherapy, biological therapies, targeted therapies, or immune-modifying treatments for any condition (confirm with trial site for exact timing details)
- People who have brain metastases (cancer that has spread to the brain) that are active, getting worse, or causing symptoms
- People who have serious or uncontrolled medical conditions, active infections, or other significant non-cancer illnesses that may pose health risks
- People who are currently pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 310-348-9636
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Characterize the safety and feasibility of TORL-1-23 in combination with chemotherapy by analyzing the incidence of treatment emergent adverse events and serious adverse events.; To assess the efficacy of neoadjuvant TORL-1-23 in combination with chemotherapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.